In patients with COPD, the add-on administration of roflumilast and other PDE4 inhibitors offers a number of benefits—primarily a lower likelihood of exacerbations (Janjua et al., 2020). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.